My Healthcare News & Research — April 13, 2026

On April 13, 2026, The Lancet Gastroenterology & Hepatology published the most comprehensive global count yet of fatty liver disease, and the headline figure is sobering. Drawing on the enormous Global Burden of Disease (GBD) 2023 dataset, an international collaboration estimated that roughly 1.3 billion people — about 16.1% of everyone alive — were living with metabolic dysfunction-associated steatotic liver disease (MASLD) in 2023, and projected that number to climb to about 1.8 billion by 2050. Below is what the analysis actually shows, what it means, and where its numbers should be read with caution.

A New Name for the World's Most Common Liver Condition

MASLD is the build-up of excess fat inside liver cells in people whose bodies are also showing metabolic strain — extra weight, high blood sugar, or abnormal blood lipids. It was renamed from non-alcoholic fatty liver disease (NAFLD) in 2023 to put the metabolic root cause front and center and to retire a label defined by what it is not. The important nuance is that most people with MASLD feel completely fine and never develop serious liver problems. The danger lies with the minority whose fatty liver progresses to inflammation (steatohepatitis, or MASH), then scarring (fibrosis), and in some cases cirrhosis or liver cancer. This study counts everyone with the condition, not only those who go on to get sick.

What the Study Actually Found

The core numbers are these. In 2023 an estimated 1.3 billion people had MASLD, an age-standardised prevalence of 14,429.3 per 100,000 population. Since 1990 the raw number of cases has jumped 142.7% — from roughly 0.5 billion to 1.3 billion — while the age-standardised prevalence rate rose a more modest 28.6%. MASLD was responsible for about 3.6 million DALYs (disability-adjusted life-years, a combined measure of years lost to early death and years lived with disability) in 2023.

Looking ahead, the model projects roughly 1.8 billion cases by 2050, a 42% increase over 2023, with the age-standardised prevalence rate edging up to 15,774.9 per 100,000. The burden is not spread evenly: the highest prevalence was in North Africa and the Middle East (29,246.1 per 100,000), while the highest DALY rate fell in Andean Latin America (152.3 per 100,000). Men had consistently higher age-standardised prevalence than women.

What Is Driving the Increase

The analysis pins the disease burden on metabolic factors. The largest contributor to MASLD-related DALYs in 2023 was high fasting plasma glucose, followed by high body-mass index and then smoking. In plain terms, this is a story about blood sugar and body weight — the same drivers behind type 2 diabetes, metabolic syndrome, and obesity.

The gap between the 142.7% jump in raw cases and the 28.6% rise in the age-standardised rate is worth pausing on. Much of the raw growth reflects a world population that is simply larger and older, not only a population that is metabolically sicker person for person. But the age-standardised rate did still rise, so per-person risk has genuinely increased too — both things are true at once.

Honest Caveats

A few limitations should temper how these figures are read. First, GBD is a modeling exercise: it stitches together surveys, published studies, and statistical estimation to fill gaps between countries and years. It is an informed estimate, not a headcount, and its uncertainty widens wherever primary data are thin — the authors specifically flag scarce data from low-resourced countries. Second, most of the underlying diagnoses rest on ultrasound, which detects moderate-to-severe liver fat well but misses mild steatosis and cannot stage fibrosis or confirm MASH (liver biopsy and, increasingly, elastography remain the reference tools). That can push the prevalence estimate in either direction.

Third, and most important for readers: prevalence is not severity. Having MASLD is common and frequently benign. A billion-plus cases is not a billion damaged livers — it is a large pool of mostly stable fatty livers plus a smaller, far more consequential group progressing toward fibrosis and its complications. Finally, the 2050 projections assume today's demographic and metabolic trends broadly continue; they are plausible scenarios, not fixed forecasts.

The Takeaway

The encouraging flip side of a metabolic diagnosis is that the forces inflating these numbers are largely modifiable. Losing even 5–10% of body weight, improving blood-sugar control, staying physically active, and limiting alcohol remain the backbone of care, now joined by the first medications approved specifically for MASH. For individuals the practical message is concrete: if you have type 2 diabetes, obesity, or metabolic syndrome, it is reasonable to ask your clinician for a simple liver check — an ALT blood test plus a FIB-4 score, and elastography if either is abnormal. Supportive habits that have at least observational backing, such as drinking coffee (two or more cups a day is associated with less fibrosis) and, in selected non-diabetic MASH patients under medical guidance, vitamin E, are reasonable adjuncts — not cures, and not substitutes for the metabolic basics. Herbal options such as milk thistle are widely used but carry weak evidence and should not delay proven care. The study's real value is scale: it tells health systems that fatty liver is now one of the most common chronic conditions on earth, and that the levers to bend the curve are the familiar ones of blood sugar and weight.

Sources